1031 related articles for article (PubMed ID: 11836600)
21. Frequent impact of [18F]fluorodeoxyglucose positron emission tomography on the staging and management of patients with indolent non-Hodgkin's lymphoma.
Blum RH; Seymour JF; Wirth A; MacManus M; Hicks RJ
Clin Lymphoma; 2003 Jun; 4(1):43-9. PubMed ID: 12837154
[TBL] [Abstract][Full Text] [Related]
22. Prognostic value of FDG-PET in malignant lymphoma.
Becherer A; Jaeger U; Szabo M; Kletter K
Q J Nucl Med; 2003 Mar; 47(1):14-21. PubMed ID: 12714950
[TBL] [Abstract][Full Text] [Related]
23. Whole-body 2-[18F]-fluoro-2-deoxy-D-glucose positron emission tomography (FDG-PET) for accurate staging of Hodgkin's disease.
Bangerter M; Moog F; Buchmann I; Kotzerke J; Griesshammer M; Hafner M; Elsner K; Frickhofen N; Reske SN; Bergmann L
Ann Oncol; 1998 Oct; 9(10):1117-22. PubMed ID: 9834825
[TBL] [Abstract][Full Text] [Related]
24. (18)F-FDG PET in Pediatric Lymphomas: A Comparison with Conventional Imaging.
Lopci E; Burnelli R; Ambrosini V; Nanni C; Castellucci P; Biassoni L; Rubello D; Fanti S
Cancer Biother Radiopharm; 2008 Dec; 23(6):681-90. PubMed ID: 19111053
[TBL] [Abstract][Full Text] [Related]
25. Direct comparison of 18F-fluorodeoxyglucose coincidence gamma camera tomography with gallium scanning for the staging of lymphoma.
Lin P; Chu J; Kneebone A; Moylan E; Jalaludin B; Pocock N; Kiat H; Rosenfeld D
Intern Med J; 2005 Feb; 35(2):91-6. PubMed ID: 15705137
[TBL] [Abstract][Full Text] [Related]
26. FDG PET can replace bone scintigraphy in primary staging of malignant lymphoma.
Moog F; Kotzerke J; Reske SN
J Nucl Med; 1999 Sep; 40(9):1407-13. PubMed ID: 10492357
[TBL] [Abstract][Full Text] [Related]
27. Fluorine-18 fluorodeoxyglucose PET/CT patterns of extranodal involvement in patients with Non-Hodgkin lymphoma and Hodgkin's disease.
Even-Sapir E; Lievshitz G; Perry C; Herishanu Y; Lerman H; Metser U
Radiol Clin North Am; 2007 Jul; 45(4):697-709, vii. PubMed ID: 17706534
[TBL] [Abstract][Full Text] [Related]
28. [(18)F]FDG in childhood lymphoma: clinical utility and impact on management.
Montravers F; McNamara D; Landman-Parker J; Grahek D; Kerrou K; Younsi N; Wioland M; Leverger G; Talbot JN
Eur J Nucl Med Mol Imaging; 2002 Sep; 29(9):1155-65. PubMed ID: 12192560
[TBL] [Abstract][Full Text] [Related]
29. 18F-FDG PET in malignant lymphoma: significance of positive findings.
Castellucci P; Zinzani P; Pourdehnad M; Alinari L; Nanni C; Farsad M; Battista G; Tani M; Stefoni V; Canini R; Monetti N; Rubello D; Alavi A; Franchi R; Fanti S
Eur J Nucl Med Mol Imaging; 2005 Jul; 32(7):749-56. PubMed ID: 15785956
[TBL] [Abstract][Full Text] [Related]
30. Whole-body positron emission tomography using 18F-fluorodeoxyglucose compared to standard procedures for staging patients with Hodgkin's disease.
Jerusalem G; Beguin Y; Fassotte MF; Najjar F; Paulus P; Rigo P; Fillet G
Haematologica; 2001 Mar; 86(3):266-73. PubMed ID: 11255273
[TBL] [Abstract][Full Text] [Related]
31. Accuracy of whole-body 18F-FDP-PET for restaging malignant lymphoma.
Mikosch P; Gallowitsch HJ; Zinke-Cerwenka W; Heinisch M; Pipam W; Eibl M; Kresnik E; Unterweger O; Linkesch W; Lind P
Acta Med Austriaca; 2003; 30(2):41-7. PubMed ID: 12752087
[TBL] [Abstract][Full Text] [Related]
32. Staging, response to therapy, and restaging of lymphomas with 18F-FDG PET.
Altamirano J; Esparza JR; de la Garza Salazar J; Calvo PS; Vera SR; Chalapud Revelo JR; Estrada G
Arch Med Res; 2008 Jan; 39(1):69-77. PubMed ID: 18067998
[TBL] [Abstract][Full Text] [Related]
33. [18F]Fluorodeoxyglucose positron emission tomography for detection of bone marrow involvement in children and adolescents with Hodgkin's lymphoma.
Purz S; Mauz-Körholz C; Körholz D; Hasenclever D; Krausse A; Sorge I; Ruschke K; Stiefel M; Amthauer H; Schober O; Kranert WT; Weber WA; Haberkorn U; Hundsdörfer P; Ehlert K; Becker M; Rössler J; Kulozik AE; Sabri O; Kluge R
J Clin Oncol; 2011 Sep; 29(26):3523-8. PubMed ID: 21825262
[TBL] [Abstract][Full Text] [Related]
34. The impact of FDG positron emission tomography imaging on the management of lymphomas.
Shah N; Hoskin P; McMillan A; Gibson P; Lowe J; wong WL
Br J Radiol; 2000 May; 73(869):482-7. PubMed ID: 10884743
[TBL] [Abstract][Full Text] [Related]
35. [Computerized tomography and F-18-FDG positron emission tomography in staging of malignant lymphomas: a comparison].
Bumann D; de Wit M; Beyer W; Beese M; Lübeck M; Bücheler E; Clausen M
Rofo; 1998 May; 168(5):457-65. PubMed ID: 9617362
[TBL] [Abstract][Full Text] [Related]
36. 18F-fluorodeoxyglucose-positron emission tomography in the staging of malignant lymphoma compared with CT and 67Ga scan.
Hong SP; Hahn JS; Lee JD; Bae SW; Youn MJ
Yonsei Med J; 2003 Oct; 44(5):779-86. PubMed ID: 14584092
[TBL] [Abstract][Full Text] [Related]
37. Gallium scan in adolescents and children with Hodgkin's disease (HD). Treatment response assessment and prognostic value.
Castellani MR; Cefalo G; Terenziani M; Aliberti G; Maccauro M; Alessi A; Villano C; Bombardieri E
Q J Nucl Med; 2003 Mar; 47(1):22-30. PubMed ID: 12714951
[TBL] [Abstract][Full Text] [Related]
38. Positron emission tomography with [18F]2-fluoro-D-2-deoxyglucose (FDG-PET) predicts relapse of malignant lymphoma after high-dose therapy with stem cell transplantation.
Becherer A; Mitterbauer M; Jaeger U; Kalhs P; Greinix HT; Karanikas G; Pötzi C; Raderer M; Dudczak R; Kletter K
Leukemia; 2002 Feb; 16(2):260-7. PubMed ID: 11840293
[TBL] [Abstract][Full Text] [Related]
39. Imaging of malignant lymphomas with F-18 FDG coincidence detection positron emission tomography.
Hwang K; Park CH; Kim HC; Kim H; Yoon S; Pai M; Kim S
Clin Nucl Med; 2000 Oct; 25(10):789-95. PubMed ID: 11043718
[TBL] [Abstract][Full Text] [Related]
40. Early therapy monitoring with FDG-PET in aggressive non-Hodgkin's lymphoma and Hodgkin's lymphoma.
Torizuka T; Nakamura F; Kanno T; Futatsubashi M; Yoshikawa E; Okada H; Kobayashi M; Ouchi Y
Eur J Nucl Med Mol Imaging; 2004 Jan; 31(1):22-8. PubMed ID: 14574514
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
